Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Crysvita Filed for Add’l Indication Tumor-Induced Osteomalacia in US
January 15, 2020
- Japan Ethical Drug Sales Slip 1.1% in November 2019: Crecon
January 14, 2020
- Hisamitsu to Establish Subsidiary in Malaysia in October
January 14, 2020
- Eisai Cancer Drug Halaven Goes on Sale in China
January 14, 2020
- Kaken Files Axillary Hyperhidrosis Med in Japan
January 14, 2020
- Healios to Develop Next-Generation Cancer Immunotherapy
January 14, 2020
- Sumitomo Dainippon’s Altavant Picks Up Onspira
January 10, 2020
- Chugai Licenses KRAS-Targeting Drug to Verastem
January 10, 2020
- Keytruda Remains Top-Seller in December Drug Ranking in Japan: Encise
January 10, 2020
- Hisamitsu Starts 2 PIII Studies for NSAIDs Patch, Plans Filing by February 2022
January 10, 2020
- Bristol-Myers Japan Chief Doubles as Celgene President amid Transition
January 10, 2020
- US District Court Dismisses Asahi Kasei’s Request for Continuing Supply of Xiaflex
January 10, 2020
- Meiji Gains Japan Rights for Novel Blood Cancer Treatment from HUYA Bioscience
January 10, 2020
- Keytruda Top New Sales Generator in 2020, Enhertu Seen as Biggest Arrival: Evaluate
January 9, 2020
- Kyowa Kirin Seeks Add’l Indication for Lumicef
January 9, 2020
- Mitsubishi Chemical to Purchase 197 Million Shares of Mitsubishi Tanabe, Taking Over 90% Ownership
January 9, 2020
- ASKA Grabs Japan, South Korea Rights to Insud’s Oral Contraceptive
January 9, 2020
- Promethera Kicks Off PIIb Study of Cell-Based Therapy HepaStem for ACLF in Europe
January 9, 2020
- Chugai Chairman Pushes for Industry Shakeup, Govt Initiative to Develop Ecosystem
January 8, 2020
- Daiichi Sankyo’s Blockbuster Hopeful Enhertu Hits US Market
January 8, 2020
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…